Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Vienna
Clinical trial register · Austria

Clinical Trials in Vienna, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Austria and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1586 matching records held by the registry are in this view. Synced 14 Nov 2026, 03:18 UTC
1586
Studies in scope
all four open statuses
855
Recruiting now
open to new participants
341
Lead sponsors
across recruiting studies
Top sites
Vienna 1013 Graz 514 Linz 434 Innsbruck 396 Salzburg 292
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Medical University of Vienna144 AstraZeneca44 AbbVie27 Novartis Pharmaceuticals25 Eli Lilly and Company23 Merck Sharp & Dohme LLC22 Bristol-Myers Squibb22 Hoffmann-La Roche21 Janssen Research & Development, LLC20 Sanofi14 University of Vienna13 argenx12 Amgen11 Takeda10 Celgene10 Bayer10 Daiichi Sankyo9 Pfizer9 Boehringer Ingelheim9 Incyte Corporation9 Novo Nordisk A/S8 University Hospital, Basel, Switzerland8 Sigmund Freud PrivatUniversitat7 Exelixis7 Gilead Sciences7 Show all 352
Site location
Vienna1013 Graz514 Linz434 Innsbruck396 Salzburg292 Sankt Pölten115 Wels90 Klagenfurt64 Feldkirch51 Krems35 Wiener Neustadt34 Leoben25 Rankweil25 Braunau am Inn17 Steyr12 Vöcklabruck7 Schwaz7 Mattersburg7 Sankt Veit an der Glan7 Kufstein6 Dornbirn6 Tulln5 Wein5 Mistelbach5 Eisenstadt4 Show all 99
All 99 locations
Target enrolment
to

Trials with a site in Vienna

1013 of 1586 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Austria
Start
Not yet open
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
NCT07586150Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia
DrugSemaglutide
Ludwig-Maximilians - University of Munich
Not applicable
140
Vienna
2028-10
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Graz, Innsbruck, Vienna, Wels
2027-11-23
Not yet open
Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis
NCT07821320Endometriosis, Endometriosis (Diagnosis), Endometriosis and Dysmenorrhea, Endometriosis Associated Pelvic Pain
DrugDesloratadine
Medical University of Vienna
Phase 2
60
Vienna
2027-02
Not yet open
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
DrugCannabidiol
University of Oxford
Phase 3
586
Vienna
2026-12-01
Not yet open
Orthopedic Hospital Vienna Speising
Not applicable
40
Vienna
2026-12-01
Not yet open
Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.
NCT07480395Complex Aortic Aneurysms, Thoracoabdominal Aneurysm, Fenestrated Endovascular Aortic Repair, Endovascular Aortic Repair
W.L.Gore & Associates
Observational
400
Innsbruck, Vienna
2026-12
Not yet open
Institut National de la Santé Et de la Recherche Médicale, France
Not applicable
120
Vienna
2026-12
Not yet open
DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response
NCT07857993Rheumatic Disorder, Rheumatoid Arthritis (RA)
Centre Hospitalier Universitaire Vaudois
Not applicable
320
Vienna
2026-11-30
Recruiting
Mi2000 TICI - Post-market Implantation Study
NCT07897318Hearing Loss, Binaural, Cochlear Implantation
MED-EL Elektromedizinische Geräte GmbH
Not applicable
22
Vienna
2026-11-11
Recruiting
Mi2000 TICI Follow-up
NCT07902414Hearing Loss, Binaural, Cochlear Implantation
MED-EL Elektromedizinische Geräte GmbH
Observational
36
Vienna
2026-11-11
Not yet open
Cookies for Platelets
NCT07890467Blood Donation
Medical University of Vienna
Not applicable
42
Vienna
2026-11-06
Recruiting
Revitalis - Midface (Cheek Area)
NCT07931482Skin Smoothness
Croma-Pharma GmbH
Not applicable
80
Vienna
2026-11-04
Not yet open
Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
NCT07914829MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MetALD, Steatotic Liver Disease
Medical University of Vienna
Not applicable
174
Vienna
2026-11-01
Not yet open
YGION Biomedical GmbH
Phase 1
15
Vienna
2026-11
Not yet open
Effects of Ashwagandha Supplementation on Quality of Life and Well-Being in Women With Endometriosis
NCT07898670Endometriosis, Quality of Life, Pain, Perceived Stress
Medical University of Vienna
Not applicable
90
Vienna
2026-11
Not yet open
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
158
Linz, Vienna
2026-11
Not yet open
Sigmund Freud PrivatUniversitat
Not applicable
70
Vienna
2026-11
Recruiting
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
NCT07896421Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer, Platinum-Resistant FRα-Positive Peritoneal Cancer
AbbVie
Observational
500
Vienna
2026-10-21
Not yet open
Comparing Simulated Patients and Manikin Based Simulation in Obstetrics
NCT07857551PPH - Postpartum Hemorrhage, Eclampsia
Medical University of Vienna
Not applicable
72
Vienna
2026-10-15
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin
Daiichi Sankyo
Phase 1/2
400
Innsbruck, Vienna
2026-10-13
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
University of Oxford
Phase 3
250
Vienna
2026-10-05
Not yet open
OM336 in Sensitized Transplant Candidates
NCT07789431Highly Sensitized Patients Awaiting Kidney Transplant
Medical University of Vienna
Phase 2
12
Vienna
2026-10-01
Not yet open
Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery
NCT07612709Lung Protective Ventilation, Cardiopulmonary Bypass, High-risk Cardiac Patients, Lung Ultrasound
Medical University of Vienna
Not applicable
45
Vienna
2026-10-01
Not yet open
Fish Oil and HDL Function in Patients on Maintenance Hemodialysis
NCT07730385Kidney Failure Chronic, Cardiovascular Disease, HDL Cholesterol
Medical University of Vienna
Not applicable
40
Vienna
2026-10
Not yet open
ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
NCT00610051End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV
Biopeutics Co., Ltd
Phase 3
600
Vienna
2026-10
Not yet open
Chinese University of Hong Kong
Not applicable
150
Vienna
2026-10
Not yet open
Scienceforbrain, UAB
Not applicable
304
Vienna
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Vienna, Linz
2026-09-29
Not yet open
Centre Hospitalier Universitaire Vaudois
Not applicable
142
Vienna
2026-09-28
Recruiting
Boehringer Ingelheim
Phase 3
466
Graz, Linz, Vienna
2026-09-17
Recruiting
AstraZeneca
Phase 3
1,330
Graz, Linz, Salzburg, Vienna
2026-09-15
Not yet open
Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery
NCT07809022Dry Eye, Dry Eye Disease (DED), Dry Eye Sensation After Cataract Surgery
Medical University of Vienna
Phase 4
25
Vienna
2026-09-15
Recruiting
YOUCA App for Parents of Children With Mental Health Issues: A Pilot Study of Usability and Efficacy
NCT07766746Mental Health Help-Seeking, Mental Health Difficulties, Mental Health and General Well-being
Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
Not applicable
25
Vienna
2026-09-15
Recruiting
Takeda
Phase 3
324
Vienna, Innsbruck, Wels, Linz
2026-09-10
Recruiting
Incyte Corporation
Phase 3
426
Graz, Leoben, Linz, Vienna, Wels
2026-09-08
Not yet open
Vapor Ablation for Localized Cancer Lesions
NCT03514329Non Small Cell Lung Cancer, Metastatic Lung Cancer, Lung Cancer
Uptake Medical Technology, Inc.
Not applicable
10
Vienna
2026-09-01
Not yet open
IOL Position and Refractive Change After Nd:YAG Laser Posterior Capsulotomy
NCT07802145Posterior Capsule Opacification, Pseudophakia, Refractive Errors
Vienna Hospital Association
Observational
80
Vienna
2026-09-01
Not yet open
Medical University of Vienna
Observational
140
Vienna
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Feldkirch, Innsbruck, Linz, Sankt Pölten, Vienna, Wels, Wiener Neustadt
2026-09-01
Recruiting
Sigmund Freud PrivatUniversitat
Observational
40
Vienna
2026-09-01
Recruiting
Charite University, Berlin, Germany
Phase 3
750
Vienna
2026-09-01
By invitation
Medical University of Vienna
Not applicable
10
Vienna
2026-09-01
Recruiting
Tridem Bioscience FlexCo
Phase 1
36
Vienna
2026-09
Recruiting
AstraZeneca
Phase 3
1,072
Graz, Linz, Vienna
2026-08-31
Recruiting
Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
Not applicable
100
Vienna
2026-08-31
Recruiting
Postoperative Outcomes of a Toric AddOn Intraocular Lens After Keratoplasty and Cataract Surgery
NCT07452042Cataract and IOL Surgery, Keratoplasty, Toric Intraocular Lens Stability
Medical University of Vienna
Observational
40
Vienna
2026-08-27
Not yet open
Medical University of Vienna
Not applicable
52
Vienna
2026-08-25
Recruiting
Eli Lilly and Company
Phase 2
606
Feldbach, Klagenfurt, Linz, Vienna
2026-08-07
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Graz, Innsbruck, Vienna
2026-08-05
Not yet open
Vienna Hospital Association
Observational
200
Vienna
2026-08-01
Not yet open
Medical University of Vienna
Not applicable
50
Vienna
2026-08-01
Not yet open
From Prehabilitation to Rehabilitation (Prehab2Rehab): Digitally Supported Short-Term Prehabilitation Prior to Cardiac Surgery
NCT07716761Coronary Artery Bypass Grafting (CABG) Surgery, Heart Valve Surgery, Surgical Closure of an Atrial Septal Defect (ASD)
Ludwig Boltzmann Institute for Digital Health and Prevention
Not applicable
40
Vienna
2026-08-01
Not yet open
Vienna Hospital Association
Not applicable
110
Vienna
2026-08-01
Recruiting
Tridem Bioscience FlexCo
Phase 1
6
Vienna
2026-07-28
Recruiting
Registry for Duchenne and Becker Muscular Dystrophy
NCT07402122Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy Symptomatic Female Carrier
Dr. Andreas Ziegler
Observational
1,500
Graz, Innsbruck, Linz, Salzburg, Vienna
2026-07-13
Recruiting
Medical University Innsbruck
Phase 2
48
Graz, Innsbruck, Vienna
2026-07-13
Recruiting
Boehringer Ingelheim
Phase 3
390
Graz, Vienna
2026-07-10
Recruiting
Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin
NCT07632716Intensive Care (ICU), Critical Illness, Alcohol Misuse
Medical University of Vienna
Observational
800
Vienna
2026-07-02
Not yet open
Hospital Universitari Vall d'Hebron Research Institute
Phase 3
15,160
Vienna
2026-07-01
Not yet open
STRATegy SUccesS in High-Risk PCI With Impella CP: Evaluation of Hemodynamic Protection in Complex PCI
NCT07588399Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
Rayyan Hemetsberger
Not applicable
50
Vienna
2026-07-01
Recruiting
BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics
NCT07633366ARDS (Acute Respiratory Distress Syndrome)
Medical University of Vienna
Observational
130
Vienna
2026-07
Recruiting
AbbVie
Phase 2/3
660
Sankt Pölten, Vienna, Graz, Linz
2026-06-30
Recruiting
German CLL Study Group
Phase 2
116
Innsbruck, Vienna
2026-06-18
Recruiting
Janssen-Cilag Pharma GmbH
Observational
35
Vienna
2026-06-10
Recruiting
Bayer
Phase 3
117
Vienna, Linz
2026-06-01
Recruiting
Medical University of Vienna
Not applicable
30
Vienna
2026-06-01
Not yet open
EMG and Delta Function in Standard RTSA vs Lateralization
NCT07464977Cuff Tear Arthropathy, Omarthrosis, Rotator Cuff Tear Arthropathy
Vienna Hospital Association
Not applicable
130
Vienna
2026-06
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Graz, Salzburg, Sankt Pölten, Vienna
2026-05-27
Recruiting
Takeda
Observational
50
Vienna
2026-05-26
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Linz, Salzburg, Vienna, Wels
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Linz, Salzburg, Vienna, Wels
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Graz, Linz, Salzburg, Vienna
2026-05-21
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Graz, Mattersburg, Saint Stefan, Vienna
2026-05-21
By invitation
The Impact of Classical Music on Performance in Robotic Surgery Simulation
NCT07639788Surgical, Surgical Behaviour in the Operating Room, Da Vinci Robot, da Vinci SP Surgical System
Medical University of Vienna
Not applicable
30
Vienna
2026-05-20
Recruiting
Hoffmann-La Roche
Phase 3
138
Vienna
2026-05-15
Recruiting
Ipsen
Phase 3
350
Vienna, Graz, Innsbruck, Sankt Pölten
2026-05-14
Recruiting
Sanofi
Phase 3
300
Graz, Vienna
2026-05-12
Recruiting
PERCEPTION - Super-Early Neuroprognostication in eCPR Patients
NCT07584187Resuscitation, Extra Corporeal Life Support, ECMO, Extracorporeal Cardiopulmonary Resuscitation
Medical University of Vienna
Observational
45
Vienna
2026-05-12
Not yet open
Medical University of Vienna
Observational
80
Vienna
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Graz, Innsbruck, Linz, Salzburg, Vienna
2026-05-11
Recruiting
OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science
NCT07619144Cardiogenic Shock, Mechanical Circulatory Support, Cardiogenic Shock Post Myocardial Infarction
Medical University of Vienna
Observational
100
Vienna
2026-05-08
Recruiting
Diamens FlexCo
Observational
200
Linz, Melk, Mödling, Pöggstall, Vienna
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Salzburg, Vienna
2026-05-06
Recruiting
AstraZeneca
Phase 3
670
Linz, Salzburg, Vienna
2026-05-04
Recruiting
Collagen Peptides and Cellular Aging
NCT07456449Longevity, Healthy Aging, Biological Ageing
University of Vienna
Not applicable
125
Vienna
2026-04-22
Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
NCT07585890End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
University Medical Center Groningen
Observational
10,000
Innsbruck, Vienna
2026-04-21
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Graz, Innsbruck, Linz, Salzburg, Vienna, Wels, Wiener Neustadt
2026-04-21
Recruiting
Boehringer Ingelheim
Phase 3
670
Linz, Vienna
2026-04-13
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Vienna
2026-04-02
Recruiting
Medical University of Vienna
Not applicable
100
Vienna
2026-04-02
Active, closed
Spotlight Medical
Observational
2,200
Vienna
2026-04-01
Not yet open
Digital Application for Stroke Health
NCT07511868Haemorrhagic Stroke, Ischaemic Stroke, Transient Ischemic Attack (TIA)
VASCage GmbH
Not applicable
500
Tulln, Vienna, Graz, Innsbruck, Linz, Steyr, Vöcklabruck
2026-04-01
Recruiting
Fructose and (Aging)
NCT07757347Intestinal Permeability, Immune Response
University of Vienna
Not applicable
32
Vienna
2026-04-01
Recruiting
Prim. Prof. Dr. Oliver Findl, MBA
Not applicable
38
Vienna
2026-03-27
Recruiting
Manual- VS Auto-Strain
NCT07496424Transesophageal Echocardiography, Cardiac Anesthesia, Cardiac Surgery Patients
Bruno Mora
Observational
70
Vienna
2026-03-23
Recruiting
Medical University of Vienna
Not applicable
40
Vienna
2026-03-23
Recruiting
BioVersys SAS
Phase 1
16
Vienna
2026-03-22
Recruiting
Santen SAS
Observational
112
Vienna
2026-03-19
Recruiting
Austrian PBC Registry
NCT07598669Primary Biliary Cholangitis, Liver Cirrhosis, Portal Hypertension
Medical University of Vienna
Observational
500
Klagenfurt, Sankt Pölten, Salzburg, Vienna, Graz, Innsbruck, Linz, Wels
2026-03-18
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Vienna
2026-03-17
Recruiting
Bristol-Myers Squibb
Phase 3
850
Innsbruck, Linz, Vienna
2026-03-16
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Vienna
2026-03-09
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Vienna, Braunau am Inn, Graz, Klagenfurt, Sankt Pölten
2026-03-03
Recruiting
L-serine and Strength Training in the Elderly
NCT07466290Brain Health, Longevity, Cognitive Performance, Strength Training Effects
University of Vienna
Not applicable
126
Vienna
2026-03
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Graz, Innsbruck, Lilienfeld, Vienna
2026-02-26
Recruiting
Medical University of Vienna
Not applicable
38
Vienna
2026-02-25
Recruiting
BeFlared Versus VBX for FEVAR
NCT07424885Fenestrated Endovascular Aortic Repair
Medical University of Vienna
Not applicable
126
Vienna
2026-02-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Vienna, Innsbruck, Linz
2026-02-16
Recruiting
Prospective, Non-interventional Study Assessing Perioral Rejuvenation Procedure
NCT07398768Perioral Wrinkles, Crow's Feet, Lip Volume Enhancement, Lip Aging
Yuvell
Observational
34
Vienna
2026-02-13
Recruiting
Bayer
Phase 4
50
Sankt Pölten, Vienna, Braunau am Inn, Feldkirch
2026-02-13
Recruiting
Zealand Pharma
Phase 3
90
Vienna
2026-02-11
Recruiting
Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction
NCT07436429Myocardial Infarction (MI), ST-Elevation Myocardial Infarction, STEMI, STEMI (STE-ACS)
Medical University of Vienna
Observational
300
Vienna
2026-02-08
Recruiting
Medical University of Vienna
Observational
5,000
Vienna
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Linz, Rankweil, Vienna, Wiener Neustadt
2026-02-03
Recruiting
Sigmund Freud PrivatUniversitat
Observational
200
Vienna
2026-02-01
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Vienna
2026-01-28
Recruiting
IDEAYA Biosciences
Phase 3
520
Graz, Innsbruck, Vienna
2026-01-25
Active, closed
CSL Behring
Phase 2
84
Innsbruck, Linz, Vienna
2026-01-22
Recruiting
Sanofi
Phase 3
751
Vienna
2026-01-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Vienna, Graz, Innsbruck, Salzburg
2026-01-19
Recruiting
Vorasidenib Maintenance for IDH Mutant Astrocytoma
NCT06809322IDH-mutant Grade 2 or 3 Astrocytoma
DrugVorasidenib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
468
Innsbruck, Linz, Vienna
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Innsbruck, Vienna
2026-01-16
Recruiting
Takeda
Phase 3
183
Linz, Sankt Pölten, Vienna
2026-01-14
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
390
Vienna
2026-01-12
Recruiting
The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Postoperative Delirium
NCT07411612Delirium - Postoperative, Neuronal Damage, Blood Brain Barrier Defect, Postoperative Complications
Medical University of Vienna
Observational
1,170
Vienna
2026-01-12
Active, closed
Adaptation of Lung Transplant Recipients at Extreme Altitude
NCT07479511Lung Transplantation, Hypoxia, Altitude, High-altitude Adaptation
Medical University of Vienna
Observational
30
Vienna
2026-01-10
Not yet open
LETHE-AT: a Personalized Multidomain Lifestyle Intervention for Individuals at Increased Risk of Memory Impairment.
NCT07376135Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Medical University of Vienna
Not applicable
300
Graz, Innsbruck, Vienna
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
Innsbruck, Linz, Vienna
2026-01-07
Recruiting
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
NCT07297914Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease
DrugsBlinatumomab·Cyclophosphamide
Bambino Gesù Hospital and Research Institute
Phase 2/3
1,000
Vienna
2026-01-07
Recruiting
Biogen
Phase 2
81
Vienna
2026-01-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Linz, Rankweil, Vienna
2026-01-02
Recruiting
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
NCT07299994Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
Sigmund Freud PrivatUniversitat
Observational
462
Vienna
2026-01-01
Recruiting
University Hospital, Basel, Switzerland
Not applicable
1,060
Dornbirn, Feldkirch, Innsbruck, Linz, Vienna
2026-01-01
Not yet open
Dopamine and Insulin in Psychosis
NCT07252752First Episode Psychosis (FEP)
Medical University of Vienna
Not applicable
46
Vienna
2026-01-01
Active, closed
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
NCT07455097Intermediate-risk Prostate Cancer, High-risk Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
600
Vienna
2026-01-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Feldkirch, Linz, Salzburg, Sankt Pölten, Vienna
2025-12-31
Recruiting
European Myeloma Network B.V.
Phase 3
1,000
Linz, Vienna
2025-12-23
Active, closed
Filler Post Market Survey (FIPS)
NCT07475455Wrinkle Reduction
Croma-Pharma GmbH
Observational
33
Vienna
2025-12-22
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
Vienna
2025-12-19
Recruiting
Novo Nordisk A/S
Phase 3
332
Vienna
2025-12-18
Recruiting
Ipsen
Observational
150
Graz, Linz, Vienna
2025-12-17
Recruiting
Sigmund Freud PrivatUniversitat
Observational
1,000
Vienna
2025-12-16
Recruiting
Dosage of Early Rehabilitation of ICU Patients
NCT06960642Critical Care, Intensive Care, Critical Illness, Physiotherapy, Early Ambulation
Medical University of Vienna
Observational
6,000
Vienna
2025-12-14
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Graz, Vienna
2025-12-11
Recruiting
AbbVie
Phase 2/3
490
Vienna
2025-12-10
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
45
Vienna
2025-12-09
Recruiting
University Hospital, Basel, Switzerland
Not applicable
18,000
Vienna
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Innsbruck, Oberwart, Salzburg, Sankt Pölten, Vienna
2025-12-03
Recruiting
Eli Lilly and Company
Phase 3
7,140
Feldkirch, Graz, Linz, Mattersburg, Sankt Stefan ob Stainz, Vienna
2025-12-01
Not yet open
Sven Schneider, MD
Observational
152
Vienna
2025-12-01
Not yet open
Vienna Institute for Research in Ocular Surgery
Not applicable
30
Vienna
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Salzburg, Vienna
2025-11-30
Recruiting
Medical University of Vienna
Not applicable
20
Vienna
2025-11-28
Recruiting
Amgen
Phase 3
750
Innsbruck, Linz, Sankt Pölten, Vienna
2025-11-28
Recruiting
Debiopharm International SA
Phase 3
119
Graz, Vienna
2025-11-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Linz, Vienna
2025-11-26
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Klagenfurt, Sankt Pölten, Graz, Leoben, Innsbruck, Linz, Vienna
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Graz, Innsbruck, Vienna
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Graz, Innsbruck, Linz, Vienna
2025-11-24
Recruiting
Bayer
Phase 3
111
Vienna, Innsbruck
2025-11-19
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Innsbruck, Linz, Vienna
2025-11-11
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Graz, Innsbruck, Vienna
2025-11-10
Recruiting
Eli Lilly and Company
Phase 2
252
Vienna
2025-11-10
Recruiting
University of Vienna
Not applicable
30
Vienna
2025-11-05
Recruiting
Medical University of Vienna
Phase 1
85
Vienna
2025-11-01
Recruiting
AstraZeneca
Phase 3
400
Graz, Linz, Rankweil, Vienna
2025-10-31
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Linz, Vienna
2025-10-28
Recruiting
Novo Nordisk A/S
Phase 1
30
Innsbruck, Vienna
2025-10-23
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Linz, Salzburg, Vienna
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Graz, Innsbruck, Vienna
2025-10-22
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Vienna
2025-10-16
Recruiting
Vega Therapeutics, Inc
Phase 3
60
Vienna
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Graz, Salzburg, Vienna, Wiener Neustadt
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Salzburg, Vienna
2025-10-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Klagenfurt, Graz, Vienna
2025-10-08
Recruiting
Sanofi
Phase 3
980
Vienna
2025-10-08
Not yet open
Medical University of Vienna
Not applicable
20
Vienna
2025-10-01
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Vienna
2025-10-01
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Vienna
2025-10-01
Not yet open
Activity of Mouthwashes Againgst Entamoeba Spp.
NCT07210814Parasite Infestation
Medical University of Vienna
Not applicable
40
Vienna
2025-10-01
Not yet open
Comparing Integrative Midwife-led vs. Fragmented Inpatient Postpartum Care: Impact on Satisfaction and Transition to Motherhood
NCT07077941Maternal Health Services, Infant, Newborn, Postnatal Care, Breast Feeding
Medical University of Vienna
Not applicable
784
Vienna
2025-10-01
Recruiting
COMS for Chronic Ulcers Treatment
NCT06528873Venous Leg Ulcer, Wound Heal, Magnetic Field Exposure
Sebastian Probst
Phase 4
122
Graz, Vienna
2025-10-01
Recruiting
Sanofi
Phase 3
980
Sankt Veit an der Glan, Krems, Graz, Linz, Salzburg, Vienna
2025-10-01
Not yet open
ImmunoMRI for Assessment of Tumor-associated Macrophages
NCT07066436DLBCL - Diffuse Large B Cell Lymphoma
Medical University of Vienna
Early Phase 1
60
Vienna
2025-10
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Vienna, Innsbruck
2025-09-30
Recruiting
Daiichi Sankyo
Phase 2/3
630
Graz, Krems, Linz, Salzburg, Vienna
2025-09-26
Recruiting
TRB Chemedica International SA
Not applicable
80
Graz, Vienna
2025-09-25
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Linz, Vienna
2025-09-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Graz, Innsbruck, Salzburg, Sankt Pölten, Vienna
2025-09-11
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Braunau am Inn, Graz, Linz, Saint Stefan Ob Stainz, Salzburg, Vienna
2025-09-06
Recruiting
Evaluation of Kidney Fibrosis Via FAPI PET/CT
NCT07712679Chronic Kidney Disease
Medical University of Vienna
Not applicable
30
Vienna
2025-09-05
Recruiting
Medical University of Vienna
Observational
20
Vienna
2025-09-05
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Vienna
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Linz, Vienna
2025-08-27
Recruiting
Basilea Pharmaceutica
Phase 3
234
Linz, Vienna
2025-08-26
Recruiting
NSC-Therapeutics
Phase 1/2
90
Salzburg, Graz, Innsbruck, Vienna
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Linz, Vienna
2025-08-22
Recruiting
Sanofi
Phase 3
90
Vienna
2025-08-18
Recruiting
Medical University of Vienna
Phase 2
6
Vienna
2025-08-14
Recruiting
Austrian Breast & Colorectal Cancer Study Group
Not applicable
350
Vienna, Baden, Dornbirn, Feldkirch, Graz, Innsbruck, Linz, Salzburg
2025-08-13
Recruiting
Charite University, Berlin, Germany
Observational
50
Vienna
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Graz, Innsbruck, Linz, Vienna
2025-08-06
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Feldkirch, Salzburg, Vienna
2025-08-05
Recruiting
HOPE Against Cancer Recurrence in HCC
NCT06717919Liver Transplantation, HCC, Oncological Outcomes
Philipp Dutkowski
Phase 4
220
Innsbruck, Vienna
2025-08-01
Recruiting
AstraZeneca
Phase 3
800
Graz, Innsbruck, Vienna
2025-08-01
Not yet open
Implantica CE Reflux Ltd.
Not applicable
200
Vienna
2025-08-01
Active, closed
Boston Scientific Corporation
Observational
550
Vienna
2025-07-30
Active, closed
Vir Biotechnology, Inc.
Phase 3
150
Innsbruck, Vienna
2025-07-30
Recruiting
CSL Behring
Phase 3
20
Vienna
2025-07-28
Active, closed
Amgen
Phase 3
12,800
Feldkirch, Graz, Klagenfurt, Linz, Mattersburg, Vienna
2025-07-25
Recruiting
Pfizer
Phase 3
714
Linz, Graz, Vienna
2025-07-23
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Graz, Salzburg, Vienna
2025-07-22
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Graz, Salzburg, Vienna
2025-07-21
Recruiting
Teleflex
Not applicable
150
Vienna, Graz
2025-07-18
Recruiting
Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
NCT07159607IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)
LMU Klinikum
Observational
100
Vienna
2025-07-17
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Vienna
2025-07-17
Recruiting
Takeda
Phase 3
347
Linz, Vienna
2025-07-15
Recruiting
University Hospital, Basel, Switzerland
Phase 2
150
Vienna
2025-07-15
Recruiting
Hoffmann-La Roche
Observational
700
Krems, Linz, Vienna, Wels
2025-07-15
Recruiting
Apreo Health, Inc.
Not applicable
250
Vienna
2025-07-15
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Vienna, Salzburg
2025-07-14
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Innsbruck, Linz, Vienna
2025-07-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Braunau am Inn, Graz, Vienna, Wels
2025-07-02
Recruiting
NORCE Norwegian Research Centre AS
Not applicable
600
Vienna
2025-07-01
Recruiting
Medical University of Vienna
Observational
20,000
Vienna
2025-07-01
Recruiting
St John of God Hospital, Vienna
Observational
15
Vienna
2025-07-01
Recruiting
I-WEAR: Evaluating Wearables and Health Summaries in ICU Survivors
NCT07035106Post-Intensive Care Syndrome (PICS), Critical Illness Recovery, Coronary Artery Disease
Ludwig Boltzmann Gesellschaft
Not applicable
60
Vienna
2025-07-01
Recruiting
MedSIR
Phase 2
200
Graz, Linz, Vienna
2025-06-30
Recruiting
MedSIR
Phase 2
20
Graz, Vienna
2025-06-27
Recruiting
The Intensive Care Platform Trial
NCT06667999Intensive Care Patients, Intensive Care Unit Patients, Critical Illness
DrugAlbumin
Anders Perner
Phase 4
10,000
Vienna
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
290
Graz, Innsbruck, Vienna
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Graz, Innsbruck, Vienna
2025-06-26
Recruiting
eleva GmbH
Phase 1
39
Vienna
2025-06-26
Recruiting
An Ecological Momentary Intervention for the Reduction of Impairment in Somatic Symptom Disorder
NCT07646509Somatic Symptom Disorder (DSM-5), Impairment, Psychological Factors, Persistent Physical Symptoms
University of Vienna
Not applicable
40
Vienna
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Braunau am Inn, Graz, Klagenfurt, Linz, Salzburg, Sankt Pölten, Vienna
2025-06-25
Recruiting
INNODIA Family & Friends Early-Stage T1D Detection Protocol
NCT07118098Type 1 Diabetes (T1D), Pre Diabetes
INNODIA iVZW
Observational
30,000
Vienna
2025-06-25
Recruiting
GlaxoSmithKline
Phase 3
961
Klagenfurt, Linz, Graz, Innsbruck, Vienna
2025-06-23
Recruiting
Impact on the Absorption of Drugs in Ostomy Patients
NCT07138326Stoma Ileostomy, Ileostomy - Stoma, Colostomy - Stoma, Absorption
WiGeV Klinik Ottakring
Observational
128
Vienna
2025-06-18
Active, closed
AbbVie
Phase 3
573
Graz, Linz, Wels, Salzburg, Vienna
2025-06-17
Active, closed
Arrowhead Pharmaceuticals
Phase 3
70
Innsbruck, Linz, Vienna
2025-06-17
Recruiting
BeOne Medicines
Phase 3
630
Innsbruck, Vienna
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
Innsbruck, Vienna
2025-06-10
Active, closed
Effect of Music on Patient Comfort
NCT07206186Perioperative Anxiety
Medical University of Vienna
Not applicable
100
Vienna
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Linz, Salzburg, Vienna, Wels
2025-06-04
Active, closed
Incyte Corporation
Phase 3
9
Graz, Innsbruck, Linz, Vienna
2025-06-04
Active, closed
ExpreS2ion Biotechnologies
Phase 1
40
Graz, Linz, Vienna
2025-06-03
By invitation
Sigmund Freud PrivatUniversitat
Observational
40
Vienna
2025-06-01
Recruiting
MediWound Ltd
Phase 3
216
Graz, Vienna
2025-06-01
Recruiting
Sarcopenia in Gestational Diabetes
NCT06876090Sarcopenia, Gestational Diabetes Mellitus (GDM), Pregnancy Complications, Adverse Maternal and Neonatal Outcomes
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche
Observational
200
Vienna
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Graz, Innsbruck, Vienna
2025-05-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Innsbruck, Vienna
2025-05-19
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Graz, Sankt Pölten, Vienna
2025-05-15
Recruiting
Medical University of Vienna
Observational
50
Vienna
2025-05-12
Recruiting
Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort
NCT06511297Obesity, Aging, Aging Problems, Metabolic Syndrome
Thomas Scherer
Observational
650
Vienna, Graz
2025-05-05
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Feldkirch, Linz, Salzburg, Vienna
2025-05-05
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
Graz, Linz, Vienna
2025-04-24
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Graz, Wels, Linz, Vienna
2025-04-24
Recruiting
AbbVie
Phase 2
390
Graz, Salzburg, Vienna
2025-04-24
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Feldkirch, Linz, Sankt Pölten, Vienna
2025-04-15
Recruiting
University of Leipzig
Phase 3
1,960
Innsbruck, Vienna
2025-04-14
Recruiting
Medical University of Vienna
Observational
200
Vienna
2025-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Vienna, Graz, Innsbruck
2025-04-09
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Vienna
2025-04-01
Not yet open
Brillouin Microscopy Used to Evaluate Corneal Mechanical Properties
NCT06914817Map Dot Fingerprint Dystrophy, Post-penetrating Keratoplasty, Post-Descemet Membrane Endothelial Keratoplasty, Healthy Corneas
Vienna Institute for Research in Ocular Surgery
Not applicable
100
Vienna
2025-04-01
Recruiting
Medical University of Vienna
Not applicable
100
Vienna
2025-04-01
Recruiting
Nitrate, Exercise and Vascular Function in Midlife Women
NCT06527248Healthy, Menopause, Hypertension, Inflammation
University of Vienna
Not applicable
54
Vienna
2025-03-31
Recruiting
Eli Lilly and Company
Phase 3
700
Graz, Linz, Vienna
2025-03-27
Recruiting
AstraZeneca
Phase 3
600
Innsbruck, Linz, Vienna, Wein
2025-03-27
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Salzburg, Vienna
2025-03-25
Active, closed
Immutep S.A.S.
Phase 3
756
Graz, Vienna
2025-03-21
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Vienna
2025-03-20
Recruiting
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
DrugsZiftomenib·Cytarabine·Fludarabine
PedAL BCU, LLC
Phase 1
20
Vienna
2025-03-18
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Vienna
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Innsbruck, Sankt Pölten, Vienna
2025-03-17
Recruiting
Medical University of Vienna
Not applicable
35
Vienna
2025-03-17
Recruiting
Insel Gruppe AG, University Hospital Bern
Phase 4
906
Eisenstadt, Graz, Innsbruck, Salzburg, Vienna
2025-03-14
Active, closed
Celgene
Phase 3
960
Krems, Linz, Salzburg, Vienna
2025-03-13
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Linz, Vienna
2025-03-12
Active, closed
Prim. Prof. Dr. Oliver Findl, MBA
Observational
50
Vienna
2025-03-11
Recruiting
177Lu-DOTATATE for Recurrent Meningioma
NCT06326190Recurrent Meningioma
DrugsLuTate·Lutathera
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
136
Innsbruck, Vienna
2025-03-10
Active, closed
POROUS GmbH
Not applicable
1,600
Vienna
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Linz, Salzburg, Vienna, Wiener Neustadt
2025-03-01
Recruiting
Novartis Pharmaceuticals
Phase 3
9
Vienna
2025-02-28
Recruiting
Incyte Corporation
Phase 3
600
Graz, Innsbruck, Vienna
2025-02-28
Recruiting
Daiichi Sankyo
Phase 3
726
Graz, Innsbruck, Vienna, Wiener Neustadt
2025-02-27
Recruiting
Medical University of Vienna
Observational
500
Vienna
2025-02-25
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
Vienna
2025-02-20
Recruiting
Hannover Medical School
Not applicable
274
Innsbruck, Vienna
2025-02-19
Recruiting
Integrum
Not applicable
70
Vienna
2025-02-19
Recruiting
Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease
NCT06954311Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
Medical University Innsbruck
Observational
120
Feldkirch, Graz, Innsbruck, Klagenfurt, Linz, Salzburg, Vienna, Villach
2025-02-17
Recruiting
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Observational
150
Vienna
2025-02-13
Active, closed
Sanofi
Phase 3
231
Graz, Linz, Vienna
2025-02-12
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Graz, Vienna
2025-02-10
Recruiting
Amino Acid Loss During Continuous Renal Replacement Therapy
NCT06659835Renal Insufficiency, Kidney Failure
Medical University of Vienna
Observational
30
Vienna
2025-02-08
Active, closed
Genmab
Phase 3
584
Vienna, Innsbruck, Linz, Graz
2025-02-07
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
875
Graz, Innsbruck, Linz, Vienna
2025-02-05
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Vienna
2025-02-04
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Vienna
2025-02-01
Recruiting
AbbVie
Observational
1,200
Stockerau, Vienna, Graz
2025-01-31
Active, closed
DEO NV
Observational
10
Vienna
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Linz, Salzburg, Vienna
2025-01-29
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Salzburg, Vienna
2025-01-28
Recruiting
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Not applicable
70
Vienna
2025-01-27
Active, closed
Institut de Recherches Internationales Servier
Phase 1/2
51
Vienna
2025-01-22
Recruiting
Incyte Corporation
Phase 3
240
Graz, Innsbruck, LINZ CET, Vienna
2025-01-21
Active, closed
argenx
Phase 3
631
Vienna
2025-01-15
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
290
Vienna
2025-01-15
Recruiting
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
NCT06655428Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD
Morair Medtech, LLC
Not applicable
30
Vienna
2025-01-10
Recruiting
Medical University of Vienna
Not applicable
38
Vienna
2025-01-02
Recruiting
Takeda
Phase 3
396
Vienna, Innsbruck, Linz, Salzburg
2025-01-02
Active, closed
Medical University of Vienna
Not applicable
146
Vienna
2025-01-01
Recruiting
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.
NCT06836011ATTR Amyloidosis With Cardiomyopathy, ATTR-CM, ATTR Amyloidosis Wild Type, Mitral Regurgitation
Medical University of Vienna
Observational
600
Graz, Vienna
2025-01-01
Active, closed
argenx
Phase 3
154
Vienna
2024-12-18
Recruiting
Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention Among Pediatric Rare Disease Patients
NCT06729554Orphan Diseases, Rare Disorders, Pediatric Diseases, Inborn Errors of Metabolism Disorders
Medical University of Vienna
Not applicable
100
Graz, Innsbruck, Linz, Salzburg, Vienna
2024-12-15
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Abbott Medical Devices
Not applicable
850
Vienna
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Salzburg, Sankt Pölten, Vienna
2024-12-13
Recruiting
Basilea Pharmaceutica
Phase 3
450
Graz, Linz, Vienna
2024-12-11
Recruiting
Brightmind.AI
Not applicable
88
Vienna
2024-12-09
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Salzburg, Vienna
2024-12-09
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Vienna
2024-12-09
Active, closed
Vicore Pharma AB
Phase 2
378
Linz, Salzburg, Vienna
2024-12-09
Active, closed
Amgen
Phase 3
707
Graz, Innsbruck, Linz, Salzburg, Sankt Pölten, Vienna
2024-12-09
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Innsbruck, Linz, Schwaz, Vienna
2024-12-05
Recruiting
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
NCT06689956FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
Mayo Clinic
Observational
212
Vienna
2024-12-04
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Graz, Salzburg, Stockerau, Vienna
2024-12-04
Recruiting
University of Vienna
Observational
52
Vienna
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Vienna
2024-12-03
Active, closed
Detection of Keratoconus Progression Using Machine Learning
NCT06873399Keratoconus, Machine Learning
Vienna Institute for Research in Ocular Surgery
Observational
200
Vienna
2024-12-02
Recruiting
Perception of Pain During Gender Affirming Hormone Therapy
NCT07148921Transgender Persons, Pain Threshold, Perception of Pain, Sex Hormones
Medical University of Vienna
Observational
40
Vienna
2024-12-01
Recruiting
NORCE Norwegian Research Centre AS
Not applicable
113
Vienna
2024-12-01
Recruiting
Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO
NCT06560164Transfusion, Red Blood Cell, Extracorporeal Membrane Oxygenation, Anemia
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not applicable
526
Vienna
2024-11-26
Active, closed
Genmab
Phase 3
191
Linz, Rankweil, Vienna
2024-11-25
Active, closed
Daiichi Sankyo
Phase 3
700
Linz, Salzburg, Vienna
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Innsbruck, Krems, Rankweil, Vienna
2024-11-18
Not yet open
Sigmund Freud PrivatUniversitat
Observational
156
Vienna
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Graz, Vienna
2024-11-15
By invitation
University of Vienna
Not applicable
60
Vienna
2024-11-13
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Graz, Linz, Vienna, Wels
2024-11-12
Recruiting
University of Birmingham
Phase 1/2
160
Vienna
2024-11-11
Active, closed
Amgen
Phase 2
409
Graz, Linz, Vienna
2024-11-07
Recruiting
Eyelid Closure in Keratometry
NCT07297849Dry Eye, Ocular Surface Disease
Vienna Institute for Research in Ocular Surgery
Not applicable
29
Vienna
2024-11-07
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Graz, Vienna
2024-10-30
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Graz, Vienna
2024-10-29
Recruiting
Pericardiotomy in Cardiac Surgery
NCT06486636Atrial Fibrillation, Atrial Flutter, Cardiac Events
Population Health Research Institute
Not applicable
1,400
Vienna, Innsbruck
2024-10-21
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Graz, Linz, Vienna, Wels
2024-10-14
Recruiting
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer
Fundacio Clinic Barcelona
Not applicable
304
Graz, Leoben, Linz, Salzburg, Sankt Pölten, Vienna, Wels
2024-10-11
Active, closed
Incyte Corporation
Phase 3
349
Graz, Vienna
2024-10-10
Active, closed
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
NCT07921940Obesity & Overweight, Gestational Diabetes Mellitus (GDM), Insulin Resistance, Maternal Obesity Complicating Pregnancy
Medical University of Vienna
Not applicable
40
Vienna
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Krems, Wels, Vienna
2024-10-07
Not yet open
Plasticizer Exposure and Its Consequences on Health
NCT06512298Beta-thalassemia, Glioma, Healthy Controls, Transfusion-dependent Beta-Thalassemia
Medical University of Vienna
Observational
120
Vienna
2024-10-01
Recruiting
Age-related Changes in Retinal Oxygen Extraction in Healthy Subjects
NCT06643403Healthy Participants, Retinal Oxygen Extraction
Medical University of Vienna
Not applicable
50
Vienna
2024-09-30
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
Krems, Sankt Pölten, Graz, Leoben, Weiz, Vienna
2024-09-27
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Krems, Salzburg, Vienna, Wels
2024-09-26
Recruiting
Takeda
Observational
500
Vienna
2024-09-25
Active, closed
Hoffmann-La Roche
Phase 3
338
Vienna
2024-09-23
Recruiting
Medical University of Vienna
Phase 2
200
Vienna
2024-09-19
Active, closed
argenx
Phase 3
141
Vienna
2024-09-18
Active, closed
Vienna Institute for Research in Ocular Surgery
Observational
50
Vienna
2024-09-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
Sankt Pölten, Graz, Innsbruck, Vienna
2024-09-18
Active, closed
Hoffmann-La Roche
Phase 3
400
Innsbruck, Vienna
2024-09-17
Active, closed
Supporting Tools and Cognitive Aids for BLS
NCT06601946Basic Life Support (Simulation)
Medical University of Vienna
Not applicable
150
Vienna
2024-09-16
Recruiting
Medical University of Vienna
Observational
90
Vienna
2024-09-06
Recruiting
AbbVie
Phase 2
590
Graz, Innsbruck, Linz, Wels, Salzburg, Vienna
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Graz, Vienna
2024-09-04
Active, closed
Tectonic Therapeutic
Phase 2
191
Vienna
2024-09-04
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Vienna, Linz, Salzburg
2024-08-31
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Feldkirch, Innsbruck, Linz, Vienna, Wels-Grieskirchen
2024-08-30
Active, closed
argenx
Phase 2
33
Vienna
2024-08-30
Recruiting
Bayer
Phase 3
444
Vienna
2024-08-28
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Vienna
2024-08-26
Active, closed
Kite, A Gilead Company
Phase 3
452
Linz, Salzburg, Sankt Pölten, Vienna
2024-08-23
Recruiting
BlueSky Immunotherapies GmbH
Phase 1
12
Vienna
2024-08-23
Recruiting
Octapharma
Phase 3
120
Innsbruck, Vienna
2024-08-21
Active, closed
Diakonhjemmet Hospital
Phase 4
387
Vienna
2024-08-20
Active, closed
AbbVie
Phase 3
699
Graz, Salzburg, Vienna
2024-08-19
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Vienna
2024-08-19
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Innsbruck, Graz, Linz, Vienna
2024-08-15
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Innsbruck, Linz, Vienna, Wels
2024-08-13
Recruiting
AstraZeneca
Phase 3
620
Graz, Linz, Salzburg, Vienna, Wiener Neustadt
2024-08-12
Recruiting
Medical University of Vienna
Phase 4
182
Vienna
2024-08-12
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
102
Sankt Pölten, Vienna
2024-08-07
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Graz, Innsbruck, Vienna
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Innsbruck, Graz, Vienna
2024-08-05
Recruiting
Wilhelminenspital Vienna
Observational
130
Vienna
2024-08-01
Recruiting
AstraZeneca
Phase 3
788
Graz, Innsbruck, Linz, Vienna
2024-08-01
Recruiting
AOP Orphan Pharmaceuticals AG
Phase 3
20
Vienna
2024-07-31
Recruiting
CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation
NCT06355063Atrial Fibrillation, Surgery, Ablation of Atrial Fibrillation, Clamp Study
Pulse Biosciences, Inc.
Not applicable
30
Vienna
2024-07-31
Recruiting
NovoCure GmbH
Phase 3
734
Innsbruck, Salzburg, Vienna
2024-07-31
By invitation
AOP Orphan Pharmaceuticals AG
Observational
110
Linz, Vienna
2024-07-31
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Linz, Salzburg, Sankt Pölten, Vienna
2024-07-30
Recruiting
Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
NCT06442267Respiratory Insufficiency, Circulatory Failure, Thromboembolism, Bleeding
DrugsUnfractionated heparin·Enoxaparin
Medical University of Vienna
Phase 4
90
Vienna
2024-07-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Graz, Innsbruck, Linz, Vienna
2024-07-24
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Innsbruck, Salzburg, Sankt Pölten, Vienna
2024-07-18
Recruiting
Amgen
Phase 3
450
Graz, Linz, Rankweil, Vienna, Wiener Neustadt
2024-07-17
Active, closed
Cardiovascular and Interventional Radiological Society of Europe
Observational
400
Eisenstadt, Graz, Linz, Vienna
2024-07-15
Recruiting
Medical University of Vienna
Not applicable
240
Vienna
2024-07-10
Recruiting
AO Innovation Translation Center
Observational
76
Vienna
2024-07-10
Recruiting
AI-POD Clinical Validation Study for Obese Patients
NCT06595134Acute Cardiovascular Disease
University Hospital, Bonn
Observational
1,200
Vienna
2024-07-01
Active, closed
AstraZeneca
Phase 3
339
Graz, Innsbruck, Linz, Vienna
2024-06-29
Active, closed
AbbVie
Phase 3
1,400
Graz, Vienna
2024-06-27
Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
DrugTagraxofusp
Stemline Therapeutics, Inc.
Observational
80
Innsbruck, Linz, Salzburg, Vienna
2024-06-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Innsbruck, Linz, Wels, Salzburg, Vienna
2024-06-24
Recruiting
AstraZeneca
Phase 3
240
Graz, Vienna
2024-06-20
Active, closed
Celgene
Phase 3
850
Wels, Linz, Vienna
2024-06-19
By invitation
University of Southampton
Observational
300
Vienna
2024-06-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Linz, Vienna
2024-06-10
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Graz, Krems, Leoben, Linz, Salzburg, Sankt Pölten, Vienna, Wels
2024-06-07
Active, closed
Exelixis
Phase 2/3
600
Linz, Salzburg, Vienna
2024-06-07
Recruiting
Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
NCT06398873Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps
DrugDupilumab
Medical University of Vienna
Observational
80
Vienna
2024-06-06
Active, closed
MedSIR
Phase 2
28
Salzburg, Vienna
2024-06-05
Recruiting
Immunocore Ltd
Phase 3
680
Graz, Pölten, Salzburg, Vienna
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Vienna, Innsbruck, Salzburg
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Graz, Innsbruck, Leoben, Linz, Vienna
2024-06-03
Recruiting
I-ASV in Cardiac Surgery
NCT06178510Ventilator Lung
Medical University of Vienna
Not applicable
328
Vienna
2024-05-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Graz, Vienna
2024-05-24
Recruiting
Daiichi Sankyo
Phase 3
540
Feldkirch, Krems, Linz, Vienna
2024-05-21
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 3
122
Vienna
2024-05-21
Active, closed
AbbVie
Phase 3
421
Krems, Vienna, Graz, Linz
2024-05-19
Active, closed
Prim. Prof. Dr. Oliver Findl, MBA
Observational
114
Vienna
2024-05-16
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Linz, Vienna
2024-05-15
Recruiting
Corheart 6 LVAS Study
NCT05876000Refractory Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
53
Graz, Vienna
2024-05-14
Recruiting
Technical University of Munich
Phase 4
2,252
Vienna
2024-05-08
Recruiting
W.L.Gore & Associates
Observational
2,000
Vienna
2024-05-07
Recruiting
Medical University of Vienna
Observational
1,300
Graz, Innsbruck, Vienna
2024-05-04
Recruiting
Medical University of Vienna
Not applicable
30
Vienna
2024-05-03
Recruiting
Medical University of Vienna
Not applicable
30
Vienna
2024-05-03
Recruiting
University of Birmingham
Phase 2/3
210
Vienna
2024-05-02
Active, closed
Eli Lilly and Company
Phase 3
10,000
Braunau am Inn, Feldkirch, Graz, Innsbruck, Linz, Mattersburg, Sankt Stefan ob Stainz, Vienna
2024-04-30
Recruiting
CSL Behring
Phase 2/3
3,110
Vienna
2024-04-27
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Innsbruck, Linz, Vienna
2024-04-16
Recruiting
CARE1 Pragmatic Clinical Trial
NCT06364631Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
DrugsAxitinib·Cabozantinib·Yervoy·Ipilimumab
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
1,250
Vienna
2024-04-12
Recruiting
AstraZeneca
Phase 3
3,850
Bad Ischl, Braunau am Inn, Graz, Linz, Saint Stefan/Stainz, Salzburg, Sankt Pölten, Vienna
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Innsbruck, Krems, Linz, Rankweil, Vienna, Wels
2024-04-11
Recruiting
Cohort Study on Plant-based Diets (COPLANT Study)
NCT06323538Dietary Exposure, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Bone Loss
German Federal Institute for Risk Assessment
Observational
6,000
Vienna
2024-04-09
Active, closed
University of Heidelberg Medical Center
Phase 3
411
Krems, Linz, Salzburg, Vienna, Wels
2024-04-05
Recruiting
Prim. Prof. Dr. Oliver Findl, MBA
Observational
80
Vienna
2024-04-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Innsbruck, Linz, Vienna
2024-04-03
Recruiting
Night Shift Work and Biomarkers of Obesity Risk in Hospital and Industry Workers
NCT06288568Obesity, Shift-work Disorder, Circadian Rhythm Disorders
University of Vienna
Observational
1,000
Vienna
2024-04-01
Recruiting
Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2
NCT06025123Out-Of-Hospital Cardiac Arrest, Hypothermia, Ventricular Fibrillation
Karolinska Institutet
Not applicable
1,022
Graz, Vienna
2024-03-27
Active, closed
Gilead Sciences
Phase 2
228
Innsbruck, Salzburg, Vienna
2024-03-27
Recruiting
Italfarmaco
Phase 3
220
Wiener Neustadt, Vienna, Linz, Wels
2024-03-26
Active, closed
AbbVie
Phase 2
156
Sankt Pölten, Vienna
2024-03-23
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Innsbruck, Linz, Vienna
2024-03-15
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Linz, Salzburg, Sankt Pölten, Vienna
2024-03-14
Recruiting
Eli Lilly and Company
Phase 3
90
Vienna
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Vienna
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Linz, Vienna
2024-03-12
Recruiting
Medical University of Vienna
Phase 2
80
Vienna
2024-03-12
Recruiting
Medical University Innsbruck
Not applicable
1,350
Graz, Innsbruck, Vienna
2024-03-12
Recruiting
AtriCure, Inc.
Observational
10,000
Vienna
2024-03-11
Recruiting
Austrian Hypertrophic Cardiomyopathy Registry
NCT06368518Hypertrophic Cardiomyopathy
Medical University of Graz
Observational
1,000
Linz, Sankt Pölten, Wiener Neustadt, Salzburg, Schwarzach im Pongau, Vienna, Graz, Innsbruck
2024-03-08
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Innsbruck, Linz, Vienna
2024-03-07
Active, closed
Ryme Medical TLD Pilot Study
NCT05967091Chronic Obstructive Pulmonary Disease
Ryme Medical, Inc.
Not applicable
60
Vienna
2024-03-06
Active, closed
Eli Lilly and Company
Phase 3
17,300
Braunau am Inn, Feldkirch, Innsbruck, Linz, Mistelbach, Salzburg, Sankt Pölten, Vienna
2024-03-05
Recruiting
STICH3C Cardiac Magnetic Resonance Observational Study
NCT07133984Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Weill Medical College of Cornell University
Observational
230
Vienna
2024-03-01
By invitation
Christian Dorfer
Observational
100
Vienna
2024-03-01
Recruiting
A Prospective Randomized Trial of ECP in Subclinical AMR
NCT06112951Antibody-mediated Rejection, Lung Transplant Rejection
Medical University of Vienna
Not applicable
80
Vienna
2024-03-01
Recruiting
Rupert Lanzenberger
Not applicable
68
Vienna
2024-03-01
Recruiting
Ludwig Boltzmann Institute for Lung Health
Observational
400
Vienna
2024-02-28
Recruiting
Pulmonx Corporation
Not applicable
200
Vienna
2024-02-22
Active, closed
AstraZeneca
Phase 2
142
Vienna
2024-02-22
Recruiting
AstraZeneca
Phase 3
5,250
Bad Ischl, Braunau am Inn, Feldbach, Graz, Vienna
2024-02-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Vienna
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Graz, Vienna
2024-02-20
Active, closed
argenx
Phase 2
103
Innsbruck, Vienna
2024-02-17
Recruiting
Amicus Therapeutics
Observational
500
Vienna
2024-02-16
Active, closed
argenx
Observational
152
Vienna
2024-02-13
Active, closed
Boehringer Ingelheim
Phase 3
428
Krems, Vienna
2024-02-09
Recruiting
Medical University of Vienna
Phase 2
10
Vienna
2024-02-01
Recruiting
University of Vienna
Not applicable
24
Vienna
2024-02-01
Active, closed
Incyte Corporation
Phase 3
617
Inssbruck, Vienna
2024-01-30
Recruiting
ICU Biobank: Understanding Post-Intensive Care Syndrome (PICS)
NCT06671795Post-Intensive Care Syndrome (PICS)
Medical University of Vienna
Observational
400
Vienna
2024-01-28
Active, closed
AbbVie
Observational
427
Vienna, Graz, Innsbruck, Linz
2024-01-24
Active, closed
Sanofi
Phase 3
260
Graz, Linz, Vienna
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Salzburg, Vienna
2024-01-22
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Sankt Pölten, Vienna
2024-01-18
Recruiting
PSMA-RLT in Biochemically Recurrent PCa
NCT06220188Prostate Cancer Recurrent
DrugLu-PSMA
Medical University of Vienna
Phase 2
20
Vienna
2024-01-15
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Graz, Innsbruck, Vienna, Wels
2024-01-11
Recruiting
Transcranial Pulse Stimulation (TPS) in Post-COVID-19
NCT06178952Post-COVID-19 Syndrome, Fatigue
Medical University of Vienna
Not applicable
102
Vienna
2024-01-08
Recruiting
Medical University of Vienna
Phase 2
16
Vienna
2024-01-02
Recruiting
Edge-to-edge Mitral Valve Repair in ATTR-CM
NCT06075823Mitral Regurgitation, ATTR-Cardiomyopathy, Edge-to-Edge Mitral Valve Repair
Medical University of Vienna
Not applicable
106
Graz, Linz, Sankt Pölten, Vienna
2024-01-01
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Linz, Vienna, Wels
2023-12-28
Recruiting
Chemoablation for Low-Grade Bladder Cancer
NCT07019220Bladder (Urothelial, Transitional Cell) Cancer
DrugGemcitabine
Ekaterina Laukhtina
Phase 2
47
Vienna
2023-12-27
Active, closed
Bristol-Myers Squibb
Phase 3
190
Vienna
2023-12-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Feldkirch, Linz, Vienna
2023-12-21
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Sankt Pölten, Vienna, Linz
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Graz, Vienna
2023-12-20
Recruiting
AstraZeneca
Phase 3
1,145
Graz, Innsbruck, Linz, Salzburg, Vienna
2023-12-14
Active, closed
Subjective Pain Scoring for Subtenonal Anesthesia During Vitrectomy
NCT06830070Epiretinal Membranes, Retinal Detachment, Full Thickness Macular Hole
Prim. Prof. Dr. Oliver Findl, MBA
Observational
70
Vienna
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Leoben, Linz, Graz, Vienna, Wels
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Innsbruck, Linz, Vienna
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Linz, Salzburg, Vienna
2023-12-12
Active, closed
Sanofi
Phase 2
197
Graz, Linz, Vienna
2023-12-11
Active, closed
Aura Biosciences
Phase 3
108
Graz, Vienna
2023-12-06
Recruiting
AOP Orphan Pharmaceuticals AG
Phase 4
110
Linz, Vienna
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Innsbruck, Vienna
2023-12-06
Active, closed
Gilead Sciences
Phase 2
176
Innsbruck, Salzburg, Sankt Pölten, Vienna
2023-12-05
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
257
Linz, Vienna, Wels, Wiener Neustadt, Zams
2023-12-05
Active, closed
AnaptysBio, Inc.
Phase 2
132
Innsbruck, Salzburg, Sankt Pölten, Vienna
2023-12-04
Active, closed
AOP Orphan Pharmaceuticals AG
Phase 3
117
Graz, Innsbruck, Linz, Vienna
2023-12-04
Rows per page Showing 1–500 of 1013
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Austrian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-austria/city/vienna

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Austria and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,586 studies in total at the last sync on 14 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,013 of those studies with a site in Vienna.

How many clinical trials are recruiting in Vienna?

542 of the 1,013 studies on this page are recruiting new participants as of the 14 Nov 2026, 03:18 UTC sync. A further 49 have not yet opened recruitment, 398 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Vienna), 1,013 studies
PhaseStudiesRecruitingShare
Phase 340817940.3%
Observational23915523.6%
Not applicable17810717.6%
Phase 296409.5%
Phase 2/328192.8%
Phase 1/225132.5%
Phase 423182.3%
Phase 115111.5%
Early Phase 1100.1%

Most active sponsors

Lead sponsors with the most studies (Vienna)
Lead sponsorStudiesRecruiting
Medical University of Vienna144107
AstraZeneca4420
AbbVie279
Novartis Pharmaceuticals2510
Eli Lilly and Company2311
Bristol-Myers Squibb228
Merck Sharp & Dohme LLC2213
Hoffmann-La Roche216
Janssen Research & Development, LLC209
Sanofi146
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.